<!doctype html>
<html lang="en">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>WHO adds GLP-1RAs to essential medicines list · Newsletter</title>
<style>
:root{--bg:#0f1221;--fg:#e8ecf3;--muted:#98a2b3;--link:#74b7ff;--card:#171b2f;--btn:#2563eb;--btnText:#fff;}
*{box-sizing:border-box} body{margin:0;font-family:ui-sans-serif,system-ui,-apple-system,Segoe UI,Roboto,Inter,Arial;background:var(--bg);color:var(--fg)}
.container{max-width:920px;margin:40px auto;padding:0 16px}
.header{display:flex;justify-content:space-between;align-items:center;gap:16px}
.brand{font-size:.95rem;font-weight:700;color:#8fb5ff}
.kicker{font-size:.85rem;color:var(--muted)}
.card{background:var(--card);border-radius:14px;padding:26px;margin-top:18px;box-shadow:0 6px 24px rgba(0,0,0,.35)}
h1{font-size:2rem;margin:.2rem 0 0}
.meta{font-size:.9rem;color:var(--muted);margin:.6rem 0 1rem}
ul{margin:12px 0 18px 22px;padding:0}
li{margin:.35rem 0;line-height:1.5}
a{color:var(--link);text-decoration:none}
a:hover{text-decoration:underline}
.btns{display:flex;gap:10px;margin-top:10px}
.btn{display:inline-block;background:transparent;border:1px solid #6b7280;color:#e5e7eb;padding:8px 12px;border-radius:8px;font-size:.9rem}
.btn.primary{background:var(--btn);border-color:var(--btn);color:var(--btnText)}
.footer{margin-top:26px;font-size:.8rem;color:var(--muted);text-align:center}
hr{border:0;border-top:1px solid #2a2f48;margin:18px 0}
</style>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">Daily Finance Newsletter</div>
      <div class="kicker">5–7 key bullets per story</div>
    </div>

    <div class="card">
      <h1>WHO adds GLP-1RAs to essential medicines list</h1>
      <div class="meta">2025-09-08 17:59:13+00:00 UTC</div>
      <ul>
        <li>This has led analysts at GlobalData, parent company of Pharmaceutical Technology, to forecast that Saxenda will make just $135m in 2031 – down 91% from the $1.5bn sales seen at its peak in 2022.</li>
        <li>Meanwhile, Trulicity also offers only a small price reduction, being sold at $987 instead of the $1079.77 charge for Mounjaro.</li>
        <li>Generics to improve GLP-1RA accessibility The August 2025 US approval of Teva Pharmaceutical’s generic Saxenda has left Novo Nordisk’s version vulnerable to competition.</li>
        <li>However, WHO raised concerns about the costs of both semaglutide and tirzepatide, which come with a hefty price tag of between $997 and $1349 for a one-month prescription in the US, which the agency warns could complicat</li>
        <li>The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and type 2 diabetes (T2D) drugs.</li>
        <li>The United Nations (UN) agency has added the glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists to the EML following a review from the</li>
        <li>Saxenda is currently very similar in price to its more efficacious successor, semaglutide.</li>
      </ul>
      <div class="btns">
        <a class="btn" href="https://finance.yahoo.com/m/bb4b1ca7-94ec-368e-9014-307f68cd1bcb/who-adds-glp-1ras-to.html" target="_blank" rel="noopener nofollow">Original</a>
        <a class="btn primary" href="https://twitter.com/intent/tweet?text=WHO+adds+GLP-1RAs+to+essential+medicines+list%0A%E2%80%A2+This+has+led+analysts+at+GlobalData%2C+parent+company+of+Pharmaceutical+Technology%2C+to+forecast+that+Saxenda+will+make+just+%24135m+in+2031+%E2%80%93+down+91%25+from+the+%241.5bn+sales+seen+at+its+peak+in+2022.%0A%E2%80%A2+Meanwhile%E2%80%A6%0Ahttps%3A%2F%2Ffinance.yahoo.com%2Fm%2Fbb4b1ca7-94ec-368e-9014-307f68cd1bcb%2Fwho-adds-glp-1ras-to.html" target="_blank" rel="noopener">Share on X</a>
      </div>
      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </div>
</body>
</html>
